Search Results - antigen

18 Results

Sort By:

Human and Improved Murine Monoclonal Antibodies Against CD22

Abstract: CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown...

Published: 8/14/2024 | Inventor(s): Dimiter Dimitrov, Xiaodong Xiao, Ira Pastan

Keywords(s): antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors

Abstract: The MUC-1 tumor associated antigen has been shown to be overexpressed and/or underglycosylated in a wide range of human cancers. The C-terminus region of MUC-1 (MUC-1C) has been shown to be an oncogene and has been associated with a more aggressive phenotype in several different cancers. Scientists at NIH have identified 7 new agonist epitopes...

Published: 4/8/2024 | Inventor(s): Jeffrey Schlom, Kwong-Yok Tsang

Keywords(s): AGONIST, ANTIGEN, Epitope, MUC-1

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer

Abstract: A significant challenge in developing therapies for the treatment and prevention of cancer has been the discovery, selection, and exploitation of antigens. Researchers at the National Institute on Aging (NIA) have partially circumvented this issue in their development of novel strategies for rendering weakly or non-immunogenic, shared antigens...

Published: 4/8/2024 | Inventor(s): Bira Arya, Dan Longo, Igor Espinoza-Delgado

Keywords(s): ANTIGEN, Biragyn, CANCER VACCINE, Chemokine, National Institute on Aging, NIA

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor

Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided): PA. Protective antigen, wild type PA-3M (PA D683A, L685E, Y688K) PA-3M Cys PA-U7 PA...

Published: 7/25/2024 | Inventor(s): Stephen Leppla

Keywords(s): Acid, AMINO, Anthrax, ANTIGEN, Edema, factor, Lethal, Listed LPM Ano as of 4/15/2015, Mutants, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, RM, SUBSTITUTIONS, VJXXXX, WIXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials

Protein Nanoparticles for Antigen Display in Vaccines

The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to...

Published: 7/25/2024 | Inventor(s): Dustin McCraw, Audray Harris

Keywords(s): ANTIGEN, DC5BXX, DISPLAY, INFLUENZA, Nanoparticles, Protein, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, Application > Vaccines, TherapeuticArea > Infectious Disease

Novel Enzyme-Based Immunoassay for Simultaneous Detection of Hepatitis C Virus Antigen and Antibody in Human Serum or Plasma

CDC scientists have developed a novel enzyme immunoassay for the simultaneous detection of hepatitis C virus (HCV) core antigen and circulating HCV antibodies. Serological testing procedures for HCV circulating antibodies are well established. There is, however, a window of time between HCV infection and seroconversion that generates an opportunity...

Published: 7/25/2024 | Inventor(s): Yury Khudyakov

Keywords(s): ANTIBODY, Antibody-based, Antibody-dependent, ANTIGEN, Antigen Antibody, ANTIGEN CAPTURE ASSAY, Antigen/Ab, Antigen/antibody, ANTIGEN-ANTIBODY, Antigen-binding, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, Detection, detection system, Diagnosis, diagnostic, diagnostic in vitro, Diagnostic Kit, EIA, HCV, Hepatitis, HEPATITIS C, HEPATITIS C DIAGNOSTIC, HEPATITIS C HCV, Human, ivd, LATERAL, Novel, OID-NCHHSTP-DVH, PLASMA, SERA, SIMULTANEOUS, viral, VIRAL DIAGNOSTIC, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Consumer Products, Application > Diagnostics, Application > Occupational Safety and Health, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, ResearchProducts > Antibodies

Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2

This CDC-developed invention pertains to multivalent antigenic peptides (MAPs) that can be used in a variety of HIV/AIDS diagnostics. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is subdivided into groups M, N, and O, while HIV-2 is subdivided into subtypes A and B. Within HIV -1 group M, several different subtypes and numerous forms of recombinant...

Published: 7/25/2024 | Inventor(s): Chou-Pong Pau

Keywords(s): 0, AAXXXX, AIDS, antibodies, ANTIGEN, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4XXX, DAXXXX, Detection, DEVELOPING, DXXXXX, GROUP, HIV-1, HIV-2., LATERAL, M, MAPS, Multiple-antigenic-peptides, MULTIVALENT, N, RESEARCH MATERIAL, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Infectious Disease, Application > Occupational Safety and Health, Application > Therapeutics, Application > Consumer Products

Recombinant Polypeptides for Clinical Detection of Taenia solium and Diagnosis of Cysticercosis

CDC scientists have developed synthetic/recombinant polypeptides that can be used for the creation of inexpensive, high-quality cysticercosis diagnostic assays. Taenia solium is a species of pathogenic tapeworm. Intestinal infection with this parasite is referred to as taeniasis and it is acquired by ingestion of T. solium cysticerci found in raw...

Published: 7/25/2024 | Inventor(s): Ryan Greene, Patricia Wilkins, Kathy Hancock, Victor Tsang

Keywords(s): ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DPDM, Cloned, Compositions, DA2XXX, DAXXXX, DETECTING, diagnostic, DXXXXX, I-031-98, I-031-99, Larval, Methods, SOLIUM, TAENIA, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Occupational Safety and Health, Application > Diagnostics, ResearchProducts > Antibodies, Application > Research Materials, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Consumer Products, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Cardiology, TherapeuticArea > Oncology

Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis

This CDC-developed technology relates to novel vaccines or boosters directed against pulmonary tuberculosis. There is currently only a single vaccine against tuberculosis, the (Bacillus Calmette-Guérin) BCG vaccine. Reports suggest widely variable effectiveness for the BCG vaccine and that BCG administration has very limited success against prevention...

Published: 7/25/2024 | Inventor(s): Bonnie Plikaytis, Thomas Shinnick, Rama Amara, Mani Cheruvu, Suraj Sable

Keywords(s): Alaine, ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC1XXX, DC4XXX, DCXXXX, DXXXXX, Identification, Mucosal, MYCOBACTERIUM, OID-NCHHSTP-DTE, PROLINE, Pulmonary, respiratory, Respiratory Diseases, respiratory INFECTION, Rich, TUBERCULOSIS, Vaccine, VACCINE DEVELOPMENT, VJXXXX, VPXXXX, WIXXXX, WJXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, Application > Research Materials, TherapeuticArea > Endocrinology, TherapeuticArea > Oncology, Application > Diagnostics, TherapeuticArea > Dental, TherapeuticArea > Ophthalmology, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease, ResearchProducts > Research Equipment

Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus

This CDC invention relates to primers and probes that specifically hybridize with Heartland virus (HRTLDV), a unique member of the genus Phlebovirus. It further relates to polyclonal antibodies specific for HRTLDV proteins. Serological detection assays using HRTLDV nucleic acid molecules, proteins, probes, primers, and antibodies are provided. Importantly,...

Published: 7/25/2024 | Inventor(s): Stuart Nichol, William Nicholson, Cynthia Goldsmith, Aubree Kelly, Laura McMullan

Keywords(s): AC4XXX, ACXXXX, ANTIBODY, ANTIGEN, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA4BXX, DA4XXX, DAXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Delivery, delivery system, DEVELOPED, diagnostic, DXXXXX, GB2CXX, GB2XXX, GBXXXX, GCXXXX, GENE THERAPY, gene transfer, GXXXXX, heartland, heartland virus, Hospitalized, Identification, ISOLATES, Isolation, Methods, Missouri, Novel, PATHOGENIC, PHLEBOVIRUS, PLATFORM, Platforms, sequence, therapeutic, therapeutic candidates, THEREOF, TICK, TICK-BORNE, TICKS, TWO, Vaccine, VACCINE VECTORS, Vector, Vector-based, Vector-borne, Vector-borne diseases, VETERINARY, VETERINARY vaccine, viral, virus, VLXXXX, VOXXXX, WBXXXX, WDXXXX, WFXXXX, WIXXXX, WJXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo

Category(s): Collaboration Sought > Licensing, ResearchProducts > Antibodies, ResearchProducts > Research Equipment, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Occupational Safety and Health, Application > Consumer Products

1 2